Everest Medicines has received approval from the Taiwan Food and Drug Administration (TFDA) for its New Drug Application (NDA) for XERAVA® (eravacycline). This approval allows XERAVA® to be used for the treatment of complicated intra-abdominal infections (cIAI) in Taiwan. XERAVA® is a novel therapy that is vital for treating cIAI and other life-threatening infections.

Everest Medicines has already launched XERAVA® successfully in mainland China and Singapore after receiving approval from the National Medical Products Administration (NMPA) of China in March 2023. The drug has been well-received, with recommendations from multiple treatment guidelines in China and globally due to its effectiveness against multidrug-resistant bacterial infections.

This approval in Taiwan is a significant milestone in making XERAVA® more accessible to patients across Asia. Everest Medicines partnered with TTY Biopharm for the commercialization of XERAVA® in Taiwan, a company with a strong track record of successfully launching novel anti-infective products in the region. This partnership is expected to further enhance patient access to XERAVA® in Taiwan.